GENEVA: Negotiations on the proposed global pandemic accord have entered a decisive phase at the World Health Organization headquarters, where member states are attempting to reconcile deep divisions over equity, surveillance, and financing frameworks for future health emergencies.
Diplomatic sources confirm that deliberations are now centered on binding commitments for equitable vaccine distribution, mandatory pathogen data sharing during outbreaks, and sustainable financing mechanisms to prevent a repeat of the systemic failures witnessed during the COVID-19 crisis. However, disagreements persist over intellectual property flexibilities and the extent to which pharmaceutical manufacturing should be decentralized to low- and middle-income countries.
For South Asia — particularly Pakistan — the treaty’s final language could prove consequential. Analysts argue that without parallel investments in regulatory readiness, cold-chain systems, and regional biomanufacturing infrastructure, the benefits of global commitments may remain largely theoretical. The accord is widely viewed as a litmus test for whether global health governance can evolve beyond the inequities exposed during the pandemic.
